Why “SaMD” Is the Wrong Place to Start
On paper, Software as a Medical Device (SaMD) looks like progress.
It gives artificial intelligence in healthcare a name, a definition, and a regulatory home. Across the US, UK, Europe, and Australia, SaMD has become the accepted label for software that diagnoses, predicts, monitors, or guides treatment.
But when it comes to reimbursement, that label quickly falls apart.
Because SaMD is a regulatory term, not an economic one.
Regulators use it to answer questions about safety, risk, and clinical validity. Payers use a very different lens. Their question is blunt and unforgiving:
What changes in the system if we pay for this?
This is where many AI companies lose the plot.
Key Takeaways
- Software as a Medical Device (SaMD) is a regulatory term, not a reimbursement category
- AI medical software is reimbursed only when it reduces cost, risk, or capacity pressure
- Accuracy alone is insufficient for payer reimbursement decisions
- Real-world evidence, registries, and patient-reported outcomes are increasingly decisive
- France and the United States are developing conditional AI reimbursement models
A Category That Means Too Much and Therefore Too Little
Under the SaMD umbrella sit tools that have almost nothing in common economically:
- an AI that flags stroke on CT scans,
- software that nudges clinicians toward guideline adherence,
- digital therapeutics for chronic disease,
- workflow tools that shave minutes off documentation,
- risk engines that predict who might deteriorate next.
They are regulated the same way.
They are not reimbursed the same way and never will be.
Asking how “SaMD is reimbursed” is like asking how medicine is reimbursed without distinguishing between antibiotics, chemotherapy, and surgery. The category is real, but it is far too broad to guide payment decisions.
Payers know this. Which is why they largely ignore the label.
What Payers Actually Look For
Health systems do not reimburse technology because it is advanced, accurate, or novel. They reimburse it because it performs a recognisable economic function.
Behind closed doors, reimbursement discussions revolve around three unglamorous questions:
- Does this replace something we already pay for?
- Does it prevent a costly event we are trying to avoid?
- Does it enable care to be delivered with fewer people, fewer steps, or less risk?
If the answer is unclear, reimbursement usually stops there.
This is why so many AI-SaMD products stall commercially despite regulatory approval, pilot enthusiasm, and impressive performance metrics. Accuracy curves do not move budgets. Workflow claims do not move payment systems. Economic clarity does.
How the SaMD Framing Sends Companies Down the Wrong Path
Starting with “SaMD reimbursement” leads to predictable and expensive mistakes:
- hunting for AI billing codes that were never designed for software,
- forcing subscription models into fee-for-service systems,
- assuming payers will “create a pathway” simply because the technology is new.
They won’t.
Healthcare payment systems are conservative by design. New technology is not rewarded for novelty; it is tolerated only when it fits existing economic logic.
The irony is that the pathways companies are looking for already exist but they are invisible if you are focused on what the software is, rather than what it does to cost, risk, or capacity.
The Reframe That Changes Everything
The companies that succeed do not pitch themselves as SaMD.
They describe themselves as:
- a way to avoid admissions,
- a mechanism to prioritise scarce specialists,
- a tool to reduce complications inside a bundled payment,
- or a risk filter for value-based care contracts.
In other words, they stop talking like technologists and start talking like stewards of a healthcare budget.
The Four Ways AI Software Actually Gets Paid
Strip away the terminology, and the pattern becomes hard to ignore.
Across healthcare systems, countries, and payment models, AI software gets reimbursed only when it plays a role the system already knows how to pay for. Not because it is artificial intelligence. Not because it is software. And certainly not because it carries a regulatory label.
It gets paid when it behaves like something familiar.
Over time, four such roles keep reappearing quietly, inconsistently, but reliably. Almost every AI tool that reaches sustained reimbursement fits one of them. Most of those that don’t eventually disappear into pilots, press releases, and procurement limbo.
When AI Saves Money Where It Hurts
The simplest case is also the most compelling.
Some AI tools reduce costs where healthcare systems already feel pain: hospital beds, complications, delays, and avoidable escalation. They don’t add new services; they change what happens inside existing ones.
Think of software that speeds up stroke triage, flags sepsis early, or prevents a patient from deteriorating overnight. Its value doesn’t need a new billing code. It shows up elsewhere fewer bed days, fewer adverse events, fewer expensive downstream decisions.
These tools are rarely reimbursed explicitly. They are absorbed instead into bundled payments and hospital budgets, tolerated because the overall episode becomes cheaper or safer with them in place.
From a payer’s point of view, the logic is brutally practical: if the total bill goes down, the software belongs inside it.
When AI Quietly Multiplies Human Capacity
Healthcare systems like to talk about innovation. What actually constrains them, day to day, is staff.
Radiologists, nurses, pathologists, specialists there are never enough of them. Software that allows the same workforce to do more without cutting corners solves a problem that keeps hospital managers awake at night.
This is where AI that automates routine tasks, prioritises workloads, or shortens reporting time earns its keep. Not as a reimbursed service, but as an operational tool.
The important detail is this: the financial benefit accrues to providers, not insurers. That is why these tools are rarely reimbursed in the classic sense. They are bought instead by departments, hospitals, and systems because they ease pressure on overstretched teams.
Many companies stumble here, chasing payer reimbursement for tools whose real economic value sits firmly inside provider operations. The result is frustration on both sides.
When AI Decides Who Needs Care and Who Doesn’t (Yet)
A growing share of AI software doesn’t treat patients at all. It sorts them.
These tools predict deterioration, flag risk, and decide who needs attention first. Their value is subtle but powerful: fewer surprises, better prioritisation, fewer costly emergencies.
This kind of software makes little sense in a fee-for-service world. Its impact unfolds across populations and over time. But in systems that carry financial risk value-based care, capitated contracts, shared-savings arrangements it suddenly becomes indispensable.
Here, reimbursement is indirect. The software is paid for because it helps someone avoid paying more later.
Trying to bill for these tools encounter by encounter almost always fails. Their logic is actuarial, not transactional.
When AI Changes the Decision Itself
Then there is the most difficult category and the one policymakers watch most closely.
Some AI systems don’t just assist clinicians. They influence, or even replace, decisions: whether to scan, admit, escalate, or treat. When that happens, the technology stops being a convenience and starts becoming part of the standard of care.
That shift brings consequences. Governance tightens. Evidence requirements rise. Liability is no longer theoretical.
These tools move slowly, but when they succeed, they attract the most serious reimbursement conversations — health technology assessments, national evaluations, conditional funding arrangements. Not because they are impressive, but because they change what the system does.
Healthcare systems are cautious here for good reason. Decisions are expensive. Mistakes are public.
Why So Many AI Tools End Up Nowhere
Most AI software doesn’t fail because it is ineffective. It fails because it does not fit cleanly into any of these roles.
It doesn’t save enough money to justify being bundled.
It doesn’t save enough time to be bought operationally.
It doesn’t manage risk at scale.
And it doesn’t carry decision-making responsibility.
These tools often attract attention, pilots, and praise, but no durable payment. They live in the gap between innovation and economics.
The Reality Check
Healthcare systems do not reimburse potential. They reimburse recognisable function.
AI software gets paid only when it behaves like something the system already understands how to value.
In the next section, we turn to the question that trips companies up even when they’ve found the right role: why technical accuracy is rarely the evidence payers are looking for and what they expect instead.
Why Accuracy Isn’t Enough
For most AI companies, the story begins — and ends — with performance.
Sensitivity. Specificity. AUROC curves. Validation cohorts. Peer-reviewed papers. These are presented as proof that reimbursement should follow naturally.
It rarely does.
Not because payers are hostile to science, but because accuracy answers the wrong question.
Regulators ask whether a tool works as intended. Payers ask whether the system behaves differently — and more cheaply or safely — once the tool is in place. Those are not the same thing.
A model can be statistically excellent and economically irrelevant at the same time.
The Scientific Gap Between Prediction and Impact
Much of AI in medicine is built on prediction: identifying patterns, estimating risk, flagging abnormalities. Scientifically, this is impressive. Clinically, it is often useful. Economically, it is incomplete.
Prediction only creates value if it changes behaviour.
An AI model that detects deterioration earlier does not save money unless someone acts on it. A triage algorithm does not reduce admissions unless pathways shift. A diagnostic aid does not lower costs unless it replaces something else — a scan, a referral, a delay.
This gap between knowing and doing is where many AI tools quietly fail.
Health systems are full of accurate information that does not change outcomes. Payers know this. Which is why they look beyond model performance to evidence that decisions, workflows, or resource use actually changed.
Why Payers Distrust Accuracy Metrics
From a payer’s perspective, accuracy metrics raise uncomfortable questions.
Does higher sensitivity increase downstream testing?
Does better detection uncover cases that would never have caused harm?
Does earlier diagnosis trigger earlier and longer treatment?
These are not academic concerns. In many cases, better detection increases cost before it reduces it.
This is why payers rarely take performance claims at face value. They have learned — often painfully — that improvements in detection can inflate utilisation without improving outcomes.
Accuracy, in other words, can create cost pressure as easily as savings.
What Counts as Evidence in the Real World
When payers talk about evidence, they mean something narrower — and more pragmatic — than many AI developers expect.
They look for signs that:
- clinicians behave differently,
- pathways are altered,
- resource use shifts,
- or risk is reduced in measurable ways.
Randomised trials are not always required. What matters is credibility: clear comparisons, realistic baselines, and outcomes that map to real costs or consequences.
This is why payers are often more persuaded by:
- changes in length of stay,
- avoided admissions,
- reduced escalation,
- or staffing efficiency,
than by incremental gains in predictive accuracy.
These outcomes speak the language of budgets.
The Problem With “Clinical Utility” Claims
Many AI companies try to bridge the gap by invoking “clinical utility.” The phrase sounds reassuring. Too often, it remains vague.
Utility, in a payer’s world, is not about helpfulness in principle. It is about what stopped happening once the tool was deployed.
What was no longer needed?
What happened less often?
What risk diminished?
If those questions remain unanswered, claims of utility carry little weight.
Why Real-World Evidence Matters and Why It’s Hard
This is where real-world evidence enters the conversation, and why it is so often misunderstood.
Payers are not asking for perfection. They are asking for believability.
Real-world data shows whether AI survives contact with clinical reality:
- messy workflows,
- partial adoption,
- alert fatigue,
- staffing shortages,
- uneven compliance.
A tool that performs beautifully in controlled studies but collapses in practice does not change system behaviour — and therefore does not earn reimbursement.
This is why payers increasingly prefer pilots, conditional funding, and phased adoption. They want to see what the software does when no one is watching.
The Uncomfortable Conclusion
Accuracy is necessary. It is not sufficient.
Healthcare systems do not pay for prediction.
They pay for changed behaviour and altered cost.
Until AI evidence is framed around that reality, reimbursement will remain elusive — no matter how good the model looks on paper.
In the next section, we examine how reimbursement actually happens in practice — through pilots, conditional coverage, and quiet workarounds that rarely make headlines, but determine whether AI survives beyond the demo stage.
Where Real-World Evidence Enters and Why Payers Care More Than They Admit
By the time most AI tools reach the reimbursement conversation, everyone in the room already knows the limitations of the evidence.
Clinical trials are small. Pilots are selective. Adoption is uneven. And the question hovering over the table is never whether the algorithm works in theory, but whether it survives contact with the health system.
This is where real-world evidence stops being a buzzword and becomes a practical necessity.
For payers, real-world evidence is not about scientific elegance. It is about reassurance — reassurance that once the software leaves the demo environment, it does not quietly inflate costs, distort behaviour, or create new risks elsewhere in the system.
Why Registries Matter More Than Studies
Traditional studies answer narrow questions under controlled conditions. Registries answer messier ones: what actually happened, to whom, and at what cost.
Well-designed registries allow payers to see patterns they cannot observe through claims data alone:
- how often alerts were acted upon,
- whether clinicians changed decisions,
- whether downstream utilisation rose or fell,
- whether outcomes improved for the patients who mattered most.
Crucially, registries shift the conversation away from promise and toward performance over time.
They also solve a problem payers rarely state openly: they need memory. Health systems forget quickly. Staff rotate. Pathways evolve. Registries preserve institutional learning, which technologies helped, which didn’t, and under what conditions.
This is why, increasingly, reimbursement discussions for AI include an unspoken requirement: show us how we can keep watching after we say yes.
The Quiet Power of Patient-Reported Outcomes
For all the focus on algorithms and automation, many of the most persuasive signals come from patients themselves.
Patient-reported outcomes, including symptoms, function, quality of life, and confidence in care, fill gaps that administrative data cannot. They show whether earlier detection actually made life better, or merely longer and more medicalised.
From a payer’s perspective, PROs do something important: they humanise cost.
A reduction in admissions is helpful. A reduction in avoidable suffering is defensible. When reimbursement decisions come under public or political scrutiny, those distinctions matter.
PROs also allow payers to detect unintended consequences early anxiety from over-monitoring, unnecessary follow-up, or alert fatigue that spills onto patients.
In that sense, PROs are not soft evidence. They are early warning systems.
Why Payers Prefer Living Evidence to Final Answers
One of the biggest misconceptions in AI reimbursement is the belief that payers want definitive proof upfront.
In reality, what they want is control.
Control over uncertainty.
Control over scale.
Control over what happens if expectations are not met.
This is why registries and ongoing outcome tracking are increasingly paired with:
- pilot reimbursement,
- conditional coverage,
- phased roll-out,
- and performance-linked continuation.
It allows payers to say yes without surrendering oversight.
A Shift Already Underway
This approach is no longer theoretical.
In several healthcare systems, including France and the United States, policymakers are actively exploring reimbursement models for AI that are explicitly tied to:
- real-world monitoring,
- post-deployment performance,
- and system-level outcomes rather than static claims.
The direction of travel is clear. AI will not be reimbursed as a one-off product. It will be paid for if at all as a continuously evaluated component of care delivery.
That shift reflects hard-earned experience. Health systems have learned that digital tools age quickly, behave unpredictably, and can drift from their original purpose. Static reimbursement models are poorly suited to that reality.
Why This Changes the Role of Evidence Generation
For AI developers, this changes the task entirely.
Evidence is no longer something you submit and move past. It becomes something you operate:
- collecting outcomes,
- tracking adoption,
- measuring behavioural change,
- and feeding results back into payer conversations.
The companies that succeed are not those with the most impressive launch studies, but those that make themselves legible to payers over time.
The Emerging Reality
In the age of AI, reimbursement is less a verdict than a relationship.
It continues only as long as the evidence continues to reassure.
Why AI Rarely Enters Healthcare Through “Permanent” Reimbursement
In healthcare, permanent reimbursement is not the starting point.
It is the end of a long process — and AI is learning that lesson the hard way.
Despite the excitement around artificial intelligence, payers have become increasingly reluctant to grant open-ended coverage to technologies whose behaviour evolves over time. Software updates. Clinical use drifts. Context changes. What worked in one hospital or population may fail quietly in another.
So instead of asking “should we reimburse this?”, payers are asking a different question:
How do we say yes without losing control?
The answer, increasingly, is temporary, conditional payment.
Pilots Are Not a Courtesy They Are a Filter
To companies, pilots often feel like a delay tactic.
To payers, they are a risk-management tool.
Pilots allow health systems to observe what AI does when:
- clinicians are busy,
- alerts compete for attention,
- adoption is partial,
- and no one is curating the results for publication.
In other words, pilots reveal whether software behaves well under pressure.
They also answer questions that formal studies often cannot:
- Does use spread organically or stall?
- Do clinicians trust it enough to change behaviour?
- Does it quietly increase downstream activity?
- Does it create new bottlenecks?
Only technologies that pass this phase move forward.
Conditional Coverage Reflects Hard Experience
Conditional reimbursement payment tied to ongoing evidence generation is sometimes framed as innovation-friendly. In truth, it is experience-hardened caution.
Health systems have learned that digital tools can:
- look stable at launch,
- perform unevenly across sites,
- and degrade over time as workflows shift.
By linking payment to continued monitoring, payers protect themselves against a familiar problem: being locked into funding something that no longer delivers.
For AI, this model fits uncomfortably well. Algorithms are not static interventions. They learn, update, and sometimes surprise their creators.
Conditional coverage allows payers to keep watching.
France, the United States and a Broader Shift
This approach is no longer confined to experimental programmes.
In France, policymakers are actively exploring ways to support AI in healthcare while retaining oversight over real-world performance, equity, and system impact. The emphasis is less on novelty and more on measurable contribution to public health priorities. In France, the Haute Autorité de Santé (HAS) is developing evaluation frameworks for health technologies incorporating AI, explicitly with the goal of informing public reimbursement decisions and building a trusted governance system around real-world performance and health system impact.
In the United States, similar thinking is emerging through pilot reimbursement, time-limited payment mechanisms, and value-linked arrangements, particularly where AI intersects with diagnostics, triage, and care management. The U.S. Centers for Medicare & Medicaid Services (CMS) has launched innovative pilot programs that test the use of AI and other enhanced technologies in payment and care models, signalling a shift toward conditional, evidence-linked payment approaches rather than traditional static reimbursement. For example, the CMS WISeR Model is a multi-year pilot that leverages AI to reduce waste and inappropriate services in Medicare and demonstrates how pilot reimbursement and payment experimentation are being used to manage technological uncertainty. https://www.cms.gov/priorities/innovation/innovation-models/wiser
The common thread is not enthusiasm or scepticism, but conditional trust.
AI is being welcomed carefully, provisionally, and with strings attached.
Why This Frustrates Companies and Reassures Payers
For technology companies, this model can feel unsatisfying. There is no clean “win.” No moment when reimbursement is secured once and for all.
For payers, that is precisely the point.
Permanent reimbursement is hard to reverse. Conditional payment is not. It preserves optionality in systems where budgets are fixed and mistakes are politically costly.
Seen from this angle, pilots and time limits are not barriers to adoption. They are the price of entry.
The New Contract Between AI and the Health System
What is emerging is a different kind of agreement.
AI tools are no longer judged once and then left alone. They are invited in on probation, expected to demonstrate value repeatedly, in real conditions, over time.
That expectation reshapes everything:
- how evidence is designed,
- how outcomes are tracked,
- how companies engage with payers,
- and how success is defined.
The Reality Check
In modern healthcare systems, reimbursement for AI is rarely a destination.
It is a monitored state sustained only as long as performance holds.
In the final section, we’ll pull these threads together and ask the question that matters most for founders, investors, and policymakers alike:
What a reimbursement-ready AI strategy actually looks like before the first payer conversation ever begins.
What a Reimbursement-Ready AI Strategy Actually Looks Like
By the time an AI product reaches a payer conversation, its fate is often already sealed.
Not because the algorithm is weak, or the science is flawed, but because reimbursement readiness was treated as something to solve later after regulatory approval, after pilots, after market entry.
Healthcare systems do not work that way.
Reimbursement is not a hurdle at the end of the journey. It is a signal, sent early and repeatedly, about whether a technology fits the system it hopes to enter.
Start With the System, Not the Software
The AI tools that eventually get paid are rarely those that begin by asking how to monetise their technology. They start by asking how healthcare budgets are already strained — and where the strain is politically and financially visible.
They understand which costs matter, which risks worry payers, and which pressures policymakers are under. They know that a solution that saves time but increases admissions will struggle, while one that slightly improves outcomes but reduces pressure on hospitals may thrive.
In other words, they design for system behaviour, not just model performance.
Evidence Is Built, Not Submitted
Successful AI companies do not treat evidence as a dossier. They treat it as infrastructure.
They plan, from the outset, how outcomes will be tracked once the software is live, how performance will be monitored across sites, and how unintended consequences will be detected early.
This makes real-world evidence generation a feature of the product, not an afterthought. It also makes payers more comfortable saying yes because oversight does not end at launch.
Expect Provisional Acceptance, Not Immediate Validation
The idea that reimbursement is a binary decision, approved or rejected, is outdated, particularly for AI.
What most health systems now offer instead is conditional acceptance: pilots, time-limited funding, and continued scrutiny. For companies that expect a decisive moment of validation, this can feel unsatisfying.
For those who understand the system, it is an opportunity.
Provisional acceptance creates space to demonstrate value in practice, to refine deployment, and to build trust over time.
The Role of Policy Is Expanding Carefully
Governments and public payers are not blind to the potential of AI. In countries such as France, and increasingly in the United States, there is active work underway to create frameworks that allow AI to contribute to public health goals without undermining budget control or equity.
But this work is cautious by design. It reflects years of experience with digital technologies that promised transformation and delivered complexity instead.
Policy is evolving but it is doing so on its own terms.
A Different Kind of Success
The AI products that endure are not always the most visible or celebrated. They are the ones that integrate quietly into care, prove their worth repeatedly, and adapt as the system around them changes.
They do not chase reimbursement as a prize. They earn it as a consequence.
The Final Reality
Healthcare does not pay for intelligence.
It pays for stability, accountability, and demonstrable impact over time.
AI software that understands this will find a place.
Those that don’t will continue to ask why reimbursement never came — long after the system has moved on.
References
Key Evidence Informing AI Software as a Medical Device (SaMD) Reimbursement
AI, Clinical Impact, and Health System Economics
- Topol, E. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine
→ Explains why AI value depends on system-level integration, not standalone accuracy. https://pubmed.ncbi.nlm.nih.gov/30617339/ - Kelly, C. J. et al. (2019). Key challenges for delivering clinical impact with artificial intelligence. BMC Medicine
→ Details why many AI tools fail to translate performance into real-world impact. https://execed-online.imperial.ac.uk/ai-in-healthcare?utm_source=Google&utm_network=g&utm_medium=c&utm_term=ai%20healthcare%20course&utm_location=9055090&utm_campaign_id=23347942011&utm_adset_id=196792615664&utm_ad_id=787849621879&gad_source=1&gad_campaignid=23347942011&gbraid=0AAAAADDa9X0b04eazfSHY5m5VABgJWyXX&gclid=Cj0KCQiAg63LBhDtARIsAJygHZ6iZa1aqC1uKjLjE7DTFvI1IjdJv7UxjR_Wj2CTe-RV9BnpCJAg5R0aAgk-EALw_wcB - Jiang, F. et al. (2017). Artificial intelligence in healthcare: past, present and future. Journal of Medical Internet Research
→ Overview of AI promise versus healthcare delivery reality.
Diagnostic Accuracy vs Real-World Performance
- McKinney, S. M. et al. (2020). International evaluation of an AI system for breast cancer screening. Nature
→ Demonstrates the gap between diagnostic accuracy and real-world implementation. - Greenhalgh, T. et al. (2017). Beyond adoption: why health technologies fail to scale. Journal of Medical Internet Research
→ Explains non-adoption, abandonment, and post-pilot failure.
Governance, Risk, and Post-Market Oversight
- WHO (2021). Ethics and governance of artificial intelligence for health.
→ Frames AI as a governance and system-risk issue, not a purely technical one. - OECD (2022). Health data governance for digital health and AI.
→ Influential in payer thinking on oversight, registries, and monitoring.
SaMD as a Regulatory Concept
- Larsen, J. et al. (2024). Software as a Medical Device (SaMD): useful or useless term?
→ Critiques SaMD as a regulatory label with limited reimbursement relevance. - University of Arizona (2024). Software as a Medical Device: regulatory and lifecycle considerations.
→ Highlights lifecycle governance and update risk relevant to reimbursement.
Reimbursement and Health Economic Frameworks
- CMS (USA). New Technology Add-On Payments (NTAP) and digital health policy materials.
→ Illustrates provisional and conditional payment approaches. - HAS / CNAM (France). Digital health and AI evaluation frameworks.
→ Reflects France’s move toward conditional, evidence-linked reimbursement. - ISPOR. Real-world evidence and health economic evaluation of digital technologies.
→ Explains why registries and cost-consequence analysis matter for AI.
Frequently Asked Questions
What is Software as a Medical Device (SaMD)?
Software as a Medical Device (SaMD) refers to software intended for medical purposes—such as diagnosis, monitoring, prediction, or treatment guidance that operates independently of a physical medical device.
Is AI Software as a Medical Device reimbursed?
In most healthcare systems, AI SaMD is not reimbursed automatically. Payment depends on whether the software demonstrably reduces cost, risk, or resource use within existing care pathways.
Why is AI SaMD rarely reimbursed through billing codes?
Because most billing systems were designed to pay for human-delivered services, not scalable software. As a result, AI SaMD rarely fits cleanly into fee-for-service reimbursement models.
How do payers decide whether to pay for AI medical software?
Payers focus on whether AI software:
- replaces something already paid for,
- prevents a costly event,
- or enables care to be delivered with fewer resources or less risk.
Accuracy alone is insufficient.
What evidence do payers require for AI reimbursement?
Payers prioritise real-world evidence showing changed clinical behaviour, reduced utilisation, improved outcomes, or measurable system-level impact rather than technical accuracy metrics alone.
Why is accuracy not enough for AI reimbursement?
Because improved detection or prediction can increase costs if it leads to more testing, referrals, or treatment. Payers look for evidence that accuracy translates into better and more efficient care.
What role does real-world evidence play in AI reimbursement?
Real-world evidence shows how AI performs in routine clinical settings, including adoption, workflow integration, and unintended consequences. It reassures payers that value persists beyond pilots.
Why are registries important for AI medical software?
Registries allow continuous monitoring of outcomes, utilisation, and performance over time. They help payers manage risk and support conditional or time-limited reimbursement decisions.
How do patient-reported outcomes (PROs influence AI reimbursement?
PROs capture patient-level benefits and harms that administrative data may miss. They help payers assess whether AI improves quality of life or creates unintended burdens.
Why is conditional reimbursement common for AI in healthcare?
Because AI systems evolve over time. Conditional reimbursement allows payers to retain oversight, adjust funding, and withdraw support if real-world performance does not meet expectations.
Which countries are developing AI reimbursement pathways?
Countries including the United States and France are actively exploring AI reimbursement models linked to real-world evidence, post-deployment monitoring, and public-health priorities.
What makes an AI product “reimbursement-ready”?
Reimbursement-ready AI software:
- fits a clear economic role,
- is designed with real-world evidence in mind,
- supports ongoing monitoring,
- and aligns with existing payment and governance structures.
Why do many AI medical products fail to achieve reimbursement?
Most fail not because they lack technical merit, but because they do not clearly demonstrate economic value or fit within established reimbursement logic.